ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sapanisertib

Also written as “Sapanisertib”, “MLN0128” and “TAK-128”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Diabetic Neuropathies · Carcinoma, Non-Small-Cell Lung · Clear-cell metastatic renal cell carcinoma, led by 3 companies.

Drug pageSapanisertib: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 27, 200514 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only80 open or runningphase 2since Sep 27, 2005Sep 27, 2005none ahead
Calithera Biosciencesits history only30 open or runningphase 2since Apr 28, 2016Jul 21, 2014none ahead
Faeth Therapeutics32 open or runningphase 2since Feb 7, 2022Feb 7, 2022Sep 2028phase 2 · NCT06463028

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Faeth Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 7, 2022First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05275673 · 7 enrolled · United States
  2. Jun 11, 2024Phase 2 study in Endometrial NeoplasmsNCT06463028 · 40 planned · United States
  3. Apr 17, 2026Phase 2 study in Breast NeoplasmsNCT07558733 · 32 planned · United States

Ahead

  1. Sep 2028Primary completion: phase 2 study in Endometrial NeoplasmsNCT06463028
  2. May 2029Primary completion: phase 2 study in Breast NeoplasmsNCT07558733

TargetBeta

MTOR →read by rule
“Serine/threonine-protein kinase mTOR inhibitor”ChEMBL 37, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
SirolimusPfizerphase 466
gedatolisibrulePfizerphase 39
PI3K/mTOR Kinase Inhibitor WXFL10030390ruleshanghai-jiatan-pharmatech-co-ltdphase 36

Studies

All 3 Faeth Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07558733Breast Neoplasms · United States2RecruitingMay 202932
NCT06463028Endometrial Neoplasms · United States2RecruitingSep 202840
NCT05275673Carcinoma, Non-Small-Cell Lung · United States2TerminatedJan 24, 20237

How it is read

Names in the registry

  • “Sapanisertib”, 5 entries
  • “MLN0128”, 4 entries
  • “TAK-128”, 4 entries
  • “TAK-228”, 2 entries
  • “sapanisertib”, 1 entry

Codes read as this program: TAK128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.